QUANTITATIVE VIRAL OUTGROWTH ASSAY (QVOA) SERVICE RESOURCE

定量病毒生长检测 (QVOA) 服务资源

• 批准号: 9149484
• 负责人: MICHAEL MURRAY
• 金额: $ 159.71万
• 依托单位: SOUTHERN RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-07-01 至 2016-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9149484
• 关键词: Biological Assay; Blood; Blood Volume; CD4 Positive T Lymphocytes; Communities; Detection; Disease; Effectiveness; HIV; HIV therapy; HIV-1; Highly Active Antiretroviral Therapy; Interphase Cell; Laboratories; Measurement; National Institute of Allergy and Infectious Disease; Patients; Performance; Research; Resources; Respondent; Rest; Services; Site; Viral; assay development; investigator training; memory CD4 T lymphocyte

HIV-1 replication can be effectively suppressed in HIV infected patients using highly active antiretroviral therapy (HAART). However, despite effective suppressive therapy, HIV has been known to exist in a state of latency, with the best characterized latent reservoir being the resting memory CD4+ T cells. These resting cells produce HIV when their resting state is reversed following cellular activation. To achieve a cure for HIV disease, the latent reservoir of HIV needs to be identified and eliminated. In order to evaluate the effectiveness of these strategies at clearing the latent reservoir, a reproducible assay capable of quantifying latent HIV is crucial. The best characterized assay today is the QVOA (Quantitative Viral Outgrowth Assay), also known as IUPM assay (Infectious Units Per Million) performed on highly purified resting CD4+ T cells under conditions that reverse latency and induce replication of HIV. However, QVOA measurements require large volumes of blood, are expensive, tedious, and labor intensive and therefore not the assay of choice for many laboratories conducting HIV eradication research. NIAID has a requirement to provide the QVOA as a service to the HIV research community. This service will allow standardized QVOA measurements so that unbiased comparisons between different eradication strategies can be achieved. Widespread use of the assay will raise the standards for latent HIV detection and reduce the need for surrogate, less accurate assays, presently used by some laboratories.

使用高活性抗逆转录病毒疗法（HAART），可以在HIV感染患者中有效抑制HIV-1复制。然而，尽管有效的抑制性疗法，但已知HIV存在于潜伏期状态，最佳特征的潜在储层是静息记忆CD4+ T细胞。当细胞激活后，这些静息细胞在静息状态逆转时会产生HIV。为了治愈艾滋病毒疾病，需要确定和消除艾滋病毒的潜在储备。 为了评估这些策略清除潜在储层的有效性，能够量化潜在艾滋病毒的可重现测定法至关重要。当今最好的特征分析是QVOA（定量病毒生长测定），在高度纯化的静息CD4+ T细胞上，在反向潜伏期和诱导HIV复制的条件下，对高度纯化的静息CD4+ T细胞进行了对IUPM测定（每百万个传染性单位）。但是，QVOA的测量需要大量的血液，昂贵，乏味且劳动密集型，因此对于许多进行HIV消除研究的实验室而言，这不是选择的分析。 NIAID需要提供QVOA作为艾滋病毒研究界的服务。该服务将允许标准化的QVOA测量值，从而可以实现不同的根除策略之间的无偏比较。该测定法的广泛使用将提高潜在艾滋病毒检测的标准，并减少对某些实验室目前使用的替代，准确测定的需求。